【摘要】 目的探讨CYP2C9和VKORC1基因多态性指导临床华法林初始抗凝的效果。方法 48例初次服用华法林的患者,按照随机分配原则分为对照组和研究组,各24例。对照组给予常规华法林方式治疗,研究组根据所检测CYP2C9和VKORC1的基因多态性来控制华法林剂量进行治疗。对比两组患者的治疗效果、国际标准化比值(INR)首次达标时间和华法林日用剂量。结果研究组总有效率91.7%高于对照组的66.7%,差异具有统计学意义(P<0.05)。研究组患者的INR首次达标时间短于对照组,华法林日用剂量少于对照组,差异均具有统计学意义(t=4.932、7.583, P<0.05)。结论运用CYP2C9和VKORC1的基因多态性来指导临床使用华法林,具有良好的临床效果,对所用华法林的剂量有一定的确定作用,值得在临床上进一步推广使用。更多还原

【Abstract】 Objective To investigate the efficacy of CYP2 C9 and VKORC1 gene polymorphisms in the guidance of clinical Warfarin initial anticoagulation. Methods A total of 48 patients who took Warfarin for the first time were divided into control group and research group according to the principle of random distribution, 24 cases in each group. The control group was treated with conventional Warfarin, the research group controlled Warfarin dose according to the detection of CYP2 C9 and VKORC1 genetic polymorphisms. The therapeutic effect, the first arrival time of international normalized ratio(INR) and Warfarin daily dose between the two groups were compared. Results The total effective rate of the research group was 91.7%, which was significantly higher than 66.7% of the control group, the difference was statistically significant(P<0.05). The first arrival time of INR in the research group was significantly shorter than that in the control group, and the Warfarin daily dose of the research group was significantly less than that of the control group, the differences were statistically significant(t=4.932, 7.583, P<0.05). Conclusion The application of CYP2 C9 and VKORC1 gene polymorphisms in the guidance of clinical use of Warfarin has good clinical effect, Warfarin dosage has a certain role in determining, it is worth further promotion and used in clinical.更多还原